HOME >> BIOLOGY >> NEWS
Can Gleevec help patients with rheumatoid arthritis?

Imatinib mesylate (Gleevec; Novartis) is often the treatment of choice for individuals with either chronic myelogenous leukemia or gastrointestinal stromal tumors. Now, in a study appearing online on September 14 in advance of publication in the October print issue of the Journal of Clinical Investigation, researchers from Stanford University have shown that imatinib can block the development of disease in a mouse model of rheumatoid arthritis (RA), providing hope of a new treatment for RA.

Although there are two documented cases in which individuals taking imatinib to treat their cancer showed clinical improvement in their RA, there had been no study of the effects of imatinib in a mouse pre-clinical model of RA. So, William Robinson and colleagues administered imatinib to mice with an RA-like disease. Imatinib both prevented the onset of disease and the development of established disease. It did this by inhibiting the function of many of the immune cells that contribute to disease in patients with RA. Importantly, imatinib was also shown to inhibit the proliferation of cells taken from the joints of patients with RA. This study indicates that imatinib might provide relief to the many individuals suffering from RA.


'"/>

Contact: Karen Honey
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
14-Sep-2006


Page: 1

Related biology news :

1. When Gleevec is not enough
2. Single genetic assay could help physicians decide when to switch patients from Gleevec to Sutent
3. Drug that battles resistance to leukemia pill Gleevec extremely effective against cancer
4. A broken stress response system can contribute to Gleevec resistance
5. First report of cancer drug Gleevec as new target therapy for pulmonary hypertension
6. Next-era targeted therapy overcoming Gleevecs shortcomings
7. New drug sidesteps Gleevec resistance in human trials
8. Abnormal fat metabolism underlies heart problems in diabetic patients
9. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
10. Aggressive therapy best for certain AML patients
11. Investigating antibiotic use in acute care patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/13/2018)... WATERBURY, Conn. (PRWEB) , ... November 13, 2018 ... ... of modern gum surgery alternatives with less invasive techniques, less discomfort ... with gum disease symptoms like receding, swollen and bleeding gums, and bad breath, ...
(Date:11/13/2018)... ... November 13, 2018 , ... Kenall has enhanced the popular ... light options. These redesigned linear overbed luminaires are equipped with symmetric ambient and asymmetric ... water and dust. , Intended to be specified in pairs, the MAEC is 8” ...
(Date:11/7/2018)... Mass. (PRWEB) , ... November 07, 2018 , ... ... special requests, and the flexibility to adjust to last-minute changes all contribute to ... Colpitts Clinical. The clinical trial patient travel and expense services provider says 80 ...
Breaking Biology News(10 mins):
(Date:10/31/2018)... (PRWEB) , ... October 30, 2018 , ... Today, the ... contest. The goal of this global competition is to find new and innovative uses ... 2017, America’s corn farmers produced 14.6 billion bushels of corn and are on pace ...
(Date:10/24/2018)... ... October 22, 2018 , ... ... Bourne, PhD, Director of the Data Science Institute, Stephenson Chair of Data Science, ... Advisory Board. Joining the board of leading scientists and doctors from around the ...
(Date:10/18/2018)... ... October 18, 2018 , ... ... laboratory in the San Francisco Bay Area has received accreditation from the College ... patient safety. , Predicine received CAP accreditation for its Shanghai facility last month. ...
(Date:10/17/2018)... ... October 17, 2018 , ... ... spp. have been validated by USDA’s Animal and Plant Health Inspection Service for ... the assays with confidence and trust, knowing they will be able to rapidly ...
Breaking Biology Technology:
Cached News: